- Home
- BDRX vs HSCS Comparison
BDRX vs HSCS Comparison
Compare BDRX & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- HSCS
- Stock Information
- Founded
- BDRX 2000
- HSCS 2007
- Country
- BDRX United Kingdom
- HSCS United States
- Employees
- BDRX N/A
- HSCS N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- BDRX Health Care
- HSCS Health Care
- Exchange
- BDRX Nasdaq
- HSCS Nasdaq
- Market Cap
- BDRX 3.7M
- HSCS 3.7M
- IPO Year
- BDRX N/A
- HSCS 2022
- Fundamental
- Price
- BDRX $1.55
- HSCS $3.20
- Analyst Decision
- BDRX
- HSCS Strong Buy
- Analyst Count
- BDRX 0
- HSCS 2
- Target Price
- BDRX N/A
- HSCS $13.00
- AVG Volume (30 Days)
- BDRX 1.2M
- HSCS 13.2K
- Earning Date
- BDRX 05-02-2025
- HSCS 03-13-2025
- Dividend Yield
- BDRX N/A
- HSCS N/A
- EPS Growth
- BDRX N/A
- HSCS N/A
- EPS
- BDRX N/A
- HSCS N/A
- Revenue
- BDRX N/A
- HSCS N/A
- Revenue This Year
- BDRX N/A
- HSCS N/A
- Revenue Next Year
- BDRX N/A
- HSCS N/A
- P/E Ratio
- BDRX N/A
- HSCS N/A
- Revenue Growth
- BDRX N/A
- HSCS 261.17
- 52 Week Low
- BDRX $1.14
- HSCS $2.36
- 52 Week High
- BDRX $74.00
- HSCS $13.50
- Technical
- Relative Strength Index (RSI)
- BDRX 43.94
- HSCS 51.24
- Support Level
- BDRX $1.24
- HSCS $2.97
- Resistance Level
- BDRX $1.52
- HSCS $3.81
- Average True Range (ATR)
- BDRX 0.20
- HSCS 0.35
- MACD
- BDRX 0.07
- HSCS 0.02
- Stochastic Oscillator
- BDRX 49.21
- HSCS 45.47
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.